DDInter397 DDInter1008
Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue to be used in topical formulations.
Clidinium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mepenzolate
Mepenzolate {u} (Compound) downregulates {v} (Gene) ACAT2
ACAT2 {u} (Gene) is upregulated by {v} (Compound) Ketoconazole
Clidinium {u} (Compound) resembles {v} (Compound) Fexofenadine
Fexofenadine {u} (Compound) binds {v} (Gene) SLCO1A2
SLCO1A2 {u} (Gene) is bound by {v} (Compound) Ketoconazole
Clidinium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mepenzolate
Mepenzolate {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Ketoconazole
Clidinium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loperamide
Loperamide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ketoconazole
Clidinium {u} (Compound) resembles {v} (Compound) Benzyl Benzoate
Benzyl Benzoate {u} (Compound) causes {v} (Side Effect) Burning sensation
Burning sensation {u} (Side Effect) is caused by {v} (Compound) Ketoconazole
Clidinium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loperamide
Loperamide {u} may lead to a major life threatening interaction when taken with {v} Posaconazole
Posaconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Clidinium {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bendroflumethiazide
Bendroflumethiazide {u} (Compound) causes {v} (Side Effect) Dizziness
Dizziness {u} (Side Effect) is caused by {v} (Compound) Ketoconazole
Clidinium {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hydrochlorothiazide
Hydrochlorothiazide {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Ketoconazole
Clidinium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loperamide
Loperamide {u} (Compound) upregulates {v} (Gene) FDFT1
FDFT1 {u} (Gene) is upregulated by {v} (Compound) Ketoconazole
Clidinium {u} may cause a minor interaction that can limit clinical effects when taken with {v} Acetaminophen
Acetaminophen {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Ketoconazole
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate (Compound) downregulates ACAT2 (Gene) and ACAT2 (Gene) is upregulated by Ketoconazole (Compound)
Clidinium (Compound) resembles Fexofenadine (Compound) and Fexofenadine (Compound) binds SLCO1A2 (Gene) and SLCO1A2 (Gene) is bound by Ketoconazole (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Ketoconazole (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ketoconazole (Compound)
Clidinium (Compound) resembles Benzyl Benzoate (Compound) and Benzyl Benzoate (Compound) causes Burning sensation (Side Effect) and Burning sensation (Side Effect) is caused by Ketoconazole (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may lead to a major life threatening interaction when taken with Posaconazole and Posaconazole (Compound) resembles Ketoconazole (Compound)
Clidinium may cause a minor interaction that can limit clinical effects when taken with Bendroflumethiazide and Bendroflumethiazide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Ketoconazole (Compound)
Clidinium may cause a minor interaction that can limit clinical effects when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Ketoconazole (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide (Compound) upregulates FDFT1 (Gene) and FDFT1 (Gene) is upregulated by Ketoconazole (Compound)
Clidinium may cause a minor interaction that can limit clinical effects when taken with Acetaminophen and Acetaminophen (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Ketoconazole (Compound)